Finerenone has 8 known drug interactions based on U.S. FDA drug labeling data. Of these, 4 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Grapefruit Juice, Grapefruit Products, Itraconazole. Patients taking Finerenone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Contraindicated
- 4
- Major
- 2
- Moderate
- 2
Contraindicated (4)
- Finerenone + Grapefruit Juice— Avoid concomitant intake of grapefruit or grapefruit juice due to increased finerenone exposure.
- Finerenone + Grapefruit Products— Avoid concomitant intake of grapefruit as it acts as a strong CYP3A4 inhibitor.
- Finerenone + Itraconazole— Co-administration is contraindicated; itraconazole increases plasma concentrations, potentially increasing pharmacologic…
- Finerenone + Mao Inhibitors— Concomitant use with strong CYP3A4 inhibitors increases finerenone exposure and may increase risk of adverse reactions.
Major (2)
- Finerenone + Cyp3a Inducers— Avoid concomitant use as it decreases finerenone exposure and may reduce efficacy of finerenone.
- Finerenone + Strong Or Moderate Cyp3a Inducers— Decreases finerenone exposure which may reduce efficacy of finerenone; avoid concomitant use.
Moderate (2)
- Finerenone + Agents Increasing Serum Potassium— More frequent serum potassium monitoring is warranted with concomitant use due to increased risk of hyperkalemia.
- Finerenone + Sensitive Cyp3a Substrates— Finerenone 40 mg is a weak CYP2C8 inhibitor and increases exposure of CYP2C8 substrates; monitor patients more frequentl…